Table 1.
Nemo | Nemo/Faslpr | Nemo/Faslpr/TNFR1−/− | |
---|---|---|---|
Neoplasia | HCCa1 | Noa2 | Noa3 |
Anisokaryosis | 4.17 ± 0.98 | 4.38 ± 0.51 | 2.88 ± 1.25c, d |
Altered foci | 2.17 ± 1.17 | 2.00 ± 1.07 | 0.62 + 0.91d |
Mitosis/HPF (40 × ) | 1.75 ± 2.47 | 1.43 ± 0.79 | 0.83 ± 1.33 |
Cellular hypertrophy | 2.5 ± 1.22 | 2.25 ± 0.46 | 1.13 ± 0.99d |
Dysplasia | 2.5 ± 1.27 | 2.30 ± 0.46 | 1.00 ± 0.93d |
Oval cell proliferation | 2.17 ± 0.98 | 1.5 ± 0.53 | 0.87 ± 0.64c, d |
Lymphoid aggregates/lymphocytic inflammation | 0.50 ± 0.00 | 1.00 ± 0.00 | 0.86 ± 0.89 |
Apoptosis | 1.50 ± 0.70 | 1.28 ± 0.48 | 0.67 ± 0.51 |
Additional lesions | Mild lipidosis diffuse vaculopathy | Multifocal necrosis | Biliary atresia early lymphomas |
a1Well-differentiated trabecular or solid HCCs
a2Early hepatocellular adenomas
a3Single well-differentiated trabecular and glandular HCC
cNemo versus Nemo/FasLPR/TNFR1−/−
dNemo/FasLPR versus Nemo/FasLPR/TNFR1−/−